AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 152 min read$MRNA

MRNA Maintains Neutral Rating -- Price Target Raised to $137

Goldman Sachs maintained a Neutral rating on Moderna (MRNA) but raised its price target to $137 from $120. GuruFocus values MRNA at $23.84, suggesting it is 849.2% overvalued. The company has a GF Score of 54/100, with strengths in financial stability but weaknesses in profitability and valuation. Insider selling totaled $49.18M over the past three months.

Original reporting
gurufocus.com
Published Oct 15, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 12:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$MRNA
Bearish
medium confidence
Mentioned
$MRNA
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$MRNABearishMed
01

Why it matters

Analyst rating updates can move the stock, but the target remains well below current price, implying limited upside and possible downside.

02

Market read

The rating change provides fresh guidance for traders, but the substantial overvaluation suggests limited bullish action.

03

What to watch

Potential upcoming data from Moderna's oncology pipeline could offset valuation concerns.

Relevance 7/10Novelty 6/10Timing: today

Background

Moderna (MRNA) is a commercial‑stage biotech with a market cap of ~$90 billion, known for its COVID‑19 vaccine Spikevax. The stock trades around $226, far above the new $137 target.

Company-level read

Ticker impact

$MRNABearishMedium confidence
Context

Goldman Sachs maintained a Neutral rating on Moderna and raised its price target from $120 to $137, a new analyst recommendation disclosed today.

Expected impact

likely pressure as the market prices in the lower target relative to the $226.30 price

Evidence & confidence

Analyst target remains far under current price, indicating the stock may be overvalued and could face selling pressure.

Market effects

Sector

Biotech sector may see modest re‑rating activity as analysts adjust targets on high‑valuation stocks.

Regional

US biotech equities could experience slight downside pressure in the short term.

Global

Limited to investors tracking Moderna and comparable mRNA companies.

Counterpoint

What could challenge this read

Despite the lower target, some investors may view the price target raise as a sign of confidence in long‑term pipeline.

Key entities

  • Analyst
    Goldman Sachs

    Maintained Neutral rating and raised price target for Moderna.

  • Company
    Moderna Inc.

    Biotech firm whose stock is the subject of the rating update.

Read at source← All news

StoryGoldman Sachs raises Moderna price target while keeping Neutral rating

Related articles

OCT 15
$MRNAMed

Moderna (MRNA) Shares Surge on Cancer Vaccine Data Ahead of Late

Moderna (MRNA) shares rose 38% since late September ahead of a presentation on late-stage trial data for its cancer vaccine, developed with Merck (MRK). The rally follows a 170% surge after positive Phase 3 melanoma trial results in August. Moderna's P/S ratio is 41.76, significantly higher than its historical median of 8.48, reflecting market growth expectations despite its unprofitability. Insider activity shows no purchases and $64.6M in sales over the past year.

gurufocus.com6 min
OCT 15
$MRNAHigh

Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?

Moderna's stock rose 658.2% year-to-date, reaching $223.60 premarket. The surge followed positive late-stage trial results for its cancer vaccine, developed with Merck. Analysts' price targets are below current levels, with a consensus at $122.67. Moderna reports Q3 earnings on November 6, with revenue and cash flow expectations to be revealed. The stock trades at 38.75 times trailing sales, raising valuation concerns.

247wallst.com2 min
OCT 14
$MRNAHigh

MRNA Stock Surges On Cancer Vaccine Catalysts And Nasdaq-100 Move

Moderna Inc. (MRNA) shares rose 4.13% on October 14, 2026, driven by optimism around its mRNA cancer vaccine pipeline and inclusion in the Nasdaq-100 Index. The company reported $143M in revenue and a net loss of $782M for the latest quarter, with $5.1B in cash reserves. Analysts have adjusted price targets, with Bank of America raising its target to $200 and Morgan Stanley to $95, both maintaining cautious ratings. The next key catalyst is Moderna's Q3 2026 earnings report on November 6, 2026.

timothysykes.com3 min
OCT 14
$MRNAMed

MRNA Stock Surges As Cancer Vaccine Hopes And Nasdaq-100 Nod Align

Moderna Inc. (MRNA) stock rose 4.22% on October 14, 2026, driven by positive mRNA pipeline data and inclusion in the Nasdaq-100 index. The company reported Q2 2026 revenue of $143M, a net loss of $782M, and has $5.14B in cash. The US NIH's cancer vaccine initiative and Moderna's oncology ambitions are key catalysts. Analysts have mixed price targets, with Bank of America at $200 and Morgan Stanley at $95.

stockstotrade.com4 min
OCT 14
$MRNAHighAI 9/10

Personalised cancer vaccines take a leap forward – can Swiss pharma catch up?

Moderna and MSD announced successful Phase III trial results for a personalized mRNA cancer vaccine, showing reduced melanoma recurrence. Roche and BioNTech halted a Phase II trial for colorectal cancer. Moderna's shares surged 60%, MSD's rose 6%. Analysts discuss implications for Swiss pharma giants Roche and Novartis, focusing on trial differences and market potential. Challenges include manufacturing time and cost.

swissinfo.ch3 min